These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9004050)

  • 21. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    Psychopharmacol Bull; 1996; 32(1):167-73. PubMed ID: 8927668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of acute intravenous clomipramine on obsessive-compulsive symptoms and response to chronic treatment.
    Mundo E; Bellodi L; Smeraldi E
    Biol Psychiatry; 1995 Oct; 38(8):525-31. PubMed ID: 8562664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacotherapy of compulsive disorders in childhood and adolescence].
    Wewetzer Ch; Mehler-Wex C; Warnke A
    Z Kinder Jugendpsychiatr Psychother; 2003 Aug; 31(3):223-30. PubMed ID: 12942794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M; Pini S; Bellantuono C; Wilkinson G
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
    Goodman WK; Kozak MJ; Liebowitz M; White KL
    Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable?
    Mundo E; Bareggi SR; Pirola R; Bellodi L
    Biol Psychiatry; 1999 Feb; 45(3):290-4. PubMed ID: 10023504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients.
    Pato MT; Hill JL; Murphy DL
    Psychopharmacol Bull; 1990; 26(2):211-4. PubMed ID: 2236458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.
    Ninan PT; Koran LM; Kiev A; Davidson JR; Rasmussen SA; Zajecka JM; Robinson DG; Crits-Christoph P; Mandel FS; Austin C
    J Clin Psychiatry; 2006 Jan; 67(1):15-22. PubMed ID: 16426083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
    Bogetto F; Bellino S; Vaschetto P; Ziero S
    Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
    Denys D; van der Wee N; van Megen HJ; Westenberg HG
    J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
    Esalatmanesh S; Abrishami Z; Zeinoddini A; Rahiminejad F; Sadeghi M; Najarzadegan MR; Shalbafan MR; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Nov; 70(11):517-526. PubMed ID: 27488081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
    Haghighi M; Jahangard L; Mohammad-Beigi H; Bajoghli H; Hafezian H; Rahimi A; Afshar H; Holsboer-Trachsler E; Brand S
    Psychopharmacology (Berl); 2013 Aug; 228(4):633-40. PubMed ID: 23525525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder.
    Karameh WK; Khani M
    Int J Neuropsychopharmacol; 2015 Jul; 19(2):. PubMed ID: 26221004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clomipramine demethylation rate is important on the outcome of obsessive-compulsive disorder treatment.
    Marcourakis T; Bernik MA; Lotufo Neto F; Gedanke Shavitt R; Gorenstein C
    Int Clin Psychopharmacol; 2015 Jan; 30(1):43-8. PubMed ID: 25279584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment.
    Cavedini P; Erzegovesi S; Ronchi P; Bellodi L
    Eur Neuropsychopharmacol; 1997 Feb; 7(1):45-9. PubMed ID: 9088884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder.
    Maina G; Albert U; Bogetto F
    Int Clin Psychopharmacol; 2001 Jan; 16(1):33-8. PubMed ID: 11195258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder.
    Fallon BA; Campeas R; Schneier FR; Hollander E; Feerick J; Hatterer J; Goetz D; Davies S; Liebowitz MR
    J Neuropsychiatry Clin Neurosci; 1992; 4(1):70-5. PubMed ID: 1627966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.